Contrast induced nephropathy medical therapy

Revision as of 19:32, 11 September 2013 by Mohamed Moubarak (talk | contribs)
Jump to navigation Jump to search

Contrast Induced Nephropathy Microchapters

Home

Patient Information

Overview

Definition

Historical Perspective

Pathophysiology

Differentiating Contrast induced nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Contrast induced nephropathy medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Contrast induced nephropathy medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Contrast induced nephropathy medical therapy

CDC on Contrast induced nephropathy medical therapy

Contrast induced nephropathy medical therapy in the news

Blogs on Contrast induced nephropathy medical therapy

Directions to Hospitals Treating Contrast induced nephropathy

Risk calculators and risk factors for Contrast induced nephropathy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Overview

Management of CIN routinely includes the avoidance of substances that are toxic to the kidneys. Dialysis is rarely required for AKI following contrast administration, but occasionally patients will require dialysis in the acute setting. The indications for dialysis are the same as in other forms of AKI.

References

Template:WH Template:WS